Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE ‐1 survodutide study

Documenti analoghi

• Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta‐analysis
  di: Ya‐Jun Xiao, et al.
  Pubblicazione: (2025)
• Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist
  di: Carel W. le Roux, et al.
  Pubblicazione: (2025)
• Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
  di: Huilin Tang, et al.
  Pubblicazione: (2025)
• Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial
  di: Koutaro Yokote, et al.
  Pubblicazione: (2026)
• Modification of the association between obesity phenotypes and cardiovascular disease by social determinants of health: A prospective cohort study
  di: Qiujin Huang, et al.
  Pubblicazione: (2026)